broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K02113016-001-19-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.713817 | 0.967281 | 0.06458 | 0.892416 | 0.267714 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001075 |
BRD-K02130563-001-11-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | -0.067718 | 0.427282 | 0.090434 | 0.514849 | 0.138275 | 0.102717 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001075 |
BRD-K03390685-001-01-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.59053 | 1.357603 | 0.078461 | 0.716914 | 0.012042 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001075 |
BRD-K03406345-001-21-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.889096 | -0.32033 | 0.014474 | 0.953059 | 0.024695 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001075 |
BRD-K03449891-001-08-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.895876 | -1.212073 | 0.151844 | 0.957802 | 0.017548 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-001075 |
BRD-K03765900-001-01-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.14679 | 0.696953 | 0.815804 | 0.653061 | 0.207006 | 0.340836 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-001075 |
BRD-K05804044-001-18-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.337566 | 0.388113 | 0.365306 | 0.736387 | 0.304333 | 5.514074 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-001075 |
BRD-K06814349-304-02-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.766246 | -2.220109 | 0.142395 | 0.884881 | 0.072606 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-001075 |
BRD-K08109215-001-06-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.150351 | 1.007573 | 0.067884 | 1 | 0.157787 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-001075 |
BRD-K08542803-001-02-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.101095 | 3.222087 | 0.486984 | 0.764004 | 0.782578 | 0.83941 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-001075 |
BRD-K08547377-001-04-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.271538 | 4.271217 | 0.415552 | 0.695441 | 0.172946 | 0.207754 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-001075 |
BRD-K08703257-001-13-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.758292 | -0.120887 | -0.094664 | 0.934097 | 0.000019 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-001075 |
BRD-K08799216-001-05-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.314088 | 0.436381 | 0.463222 | 0.606017 | 0.030992 | 0.299129 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-001075 |
BRD-K09951645-001-11-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 32.535462 | 0.469667 | -0.010649 | 1 | 37,043,455,861,925.91 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-001075 |
BRD-K11267252-001-05-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.991911 | -0.053501 | -0.011716 | 0.9953 | 36.541083 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-001075 |
BRD-K11630072-001-13-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.679861 | 0.514617 | -0.226474 | 0.914315 | 1.279677 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-001075 |
BRD-K12184916-001-19-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.668275 | -0.137737 | -0.014405 | 0.796693 | 2.411027 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-001075 |
BRD-K12343256-001-14-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.517026 | 0.47442 | 0.390226 | 0.66925 | 0.008115 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-001075 |
BRD-K13049116-001-04-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.754841 | 0.414366 | 0.039859 | 0.918051 | 0.681009 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-001075 |
BRD-K13390322-001-06-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.094618 | 7.658501 | 0.835943 | 0.733045 | 0.571862 | 0.587754 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-001075 |
BRD-K13514097-001-04-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.239308 | 0.501396 | 0.102244 | 1 | 1.164475 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-001075 |
BRD-K13662825-001-07-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.078909 | 7.67653 | 0.70179 | 0.594735 | 0.035009 | 0.035801 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-001075 |
BRD-K14109347-001-03-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.102479 | -1.01042 | -0.056799 | 1 | 193.634298 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-001075 |
BRD-K15179879-001-03-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.115394 | 1.78919 | 0.784551 | 0.463749 | 0.027848 | 0.032247 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-001075 |
BRD-K15600710-066-05-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | -0.075046 | 0.70779 | 0.651716 | 0.745262 | 1.331255 | 1.092574 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-001075 |
BRD-K16730910-001-10-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.685046 | -2.156102 | 0.135128 | 0.981954 | 0.000901 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-001075 |
BRD-K17555800-003-02-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.988324 | -0.335954 | -0.012126 | 0.993581 | 0.160339 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-001075 |
BRD-K17610631-001-03-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.391025 | 0.385114 | 0.134694 | 1 | 0.781869 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-001075 |
BRD-K17743125-001-08-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.886368 | 0.008176 | -0.000024 | 0.942749 | 0.012021 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-001075 |
BRD-K17894950-001-14-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.965488 | -0.429282 | -0.045786 | 0.978147 | 0.423045 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-001075 |
BRD-K18961567-001-01-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.746475 | 0.439168 | -0.072304 | 0.850635 | 0.025828 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-001075 |
BRD-K19540840-001-09-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.326731 | 0.632086 | 0.537976 | 0.745624 | 0.290783 | 1.55494 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-001075 |
BRD-K19687926-001-04-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.514456 | 0.551594 | 0.22354 | 0.859173 | 0.885236 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-001075 |
BRD-K19796430-001-05-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.874618 | 0.320541 | -0.020509 | 0.946088 | 0.222935 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-001075 |
BRD-K22064724-001-01-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.134162 | 2.641677 | 0.651044 | 0.778942 | 0.83981 | 0.945242 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-001075 |
BRD-K22822991-001-02-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.879932 | -1.641964 | -0.049516 | 0.947598 | 0.042127 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-001075 |
BRD-K23228615-001-02-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.287816 | 0.772261 | 0.474404 | 0.76089 | 0.425045 | 1.289628 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-001075 |
BRD-K23984367-001-07-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.793066 | -1.463836 | 0.010898 | 0.984693 | 0.000932 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-001075 |
BRD-K26026438-001-01-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.784566 | 0.089234 | -0.047844 | 0.887944 | 0.031209 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-001075 |
BRD-K26657438-001-15-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.056774 | 0.122398 | -0.034234 | 1 | 0.02551 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-001075 |
BRD-K28822270-001-03-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 2.797848 | 0.112671 | 0.005921 | 1 | 3,838,924,832.013717 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-001075 |
BRD-K29905972-001-06-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.846508 | -0.681433 | -0.037133 | 0.951863 | 0.010675 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-001075 |
BRD-K30577245-001-05-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.04661 | -0.155411 | -0.014279 | 1 | 2.034448 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-001075 |
BRD-K31698212-001-02-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.276751 | 0.65495 | 0.271832 | 0.79898 | 0.883262 | 3.025191 | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-001075 |
BRD-K31928526-001-02-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.030586 | 1.499391 | 0.010447 | 1 | 7.172393 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-001075 |
BRD-K33379087-001-07-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.710259 | -1.806504 | 0.01933 | 0.906137 | 0.014121 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-001075 |
BRD-K33610132-001-02-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.052347 | -0.138357 | 0.009888 | 1 | 0.019936 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-001075 |
BRD-K33622447-066-01-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.849072 | 0.856115 | 0.060158 | 0.93275 | 0.134784 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-001075 |
BRD-K36627727-001-05-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.550573 | -1.104928 | -0.108425 | 0.956941 | 0.001035 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001075 |
BRD-K36788280-001-01-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.942036 | -1.098141 | 0.031724 | 0.970518 | 0.084997 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-001075 |
BRD-K37379014-001-02-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 2.268374 | 1.6788 | 0.778697 | 1 | 0.017847 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001075 |
BRD-K38332599-001-01-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.020333 | -0.062832 | -0.031598 | 1 | 0.392389 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-001075 |
BRD-K38527262-300-01-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.849791 | -0.829989 | -0.021723 | 0.949069 | 0.013994 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-001075 |
BRD-K38852836-001-02-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.251799 | 1.010504 | 0.547033 | 0.683367 | 0.041712 | 0.083418 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001075 |
BRD-K39974922-001-04-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.807783 | 0.340271 | -0.172162 | 0.921446 | 0.292058 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-001075 |
BRD-K41859756-001-06-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.255276 | 2.027446 | 0.823076 | 0.637241 | 0.022164 | 0.031528 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001075 |
BRD-K42495768-001-01-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.895277 | -3.482422 | -0.006139 | 0.934748 | 0.257897 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-001075 |
BRD-K42805893-001-04-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.208178 | 1.477096 | 0.52698 | 0.800692 | 0.885531 | 1.275024 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-001075 |
BRD-K42828737-001-03-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.779632 | -0.852812 | 0.058361 | 0.94387 | 0.006222 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-001075 |
BRD-K42898655-001-01-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.932167 | -0.094431 | -0.065246 | 0.95208 | 62.09565 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001075 |
BRD-K43389675-001-02-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.035916 | 2.54464 | 0.767931 | 0.76475 | 0.937505 | 0.965375 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-001075 |
BRD-K44227013-001-06-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.263597 | 2.85044 | 0.48207 | 0.886498 | 2.2519 | 2.928721 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-001075 |
BRD-K44408410-001-17-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.183464 | 0.787402 | 0.186373 | 1 | 0.305442 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-001075 |
BRD-K44827188-001-06-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.982679 | -1.109353 | -0.000635 | 0.988764 | 0.33729 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-001075 |
BRD-K46386702-001-02-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.237913 | 0.409869 | 0.356783 | 0.778339 | 1.285506 | 6.215809 | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-001075 |
BRD-K49328571-001-15-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.241928 | 0.543573 | 0.39804 | 0.658114 | 0.135357 | 0.456964 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-001075 |
BRD-K49350383-001-14-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.981138 | 0.130532 | -0.069024 | 0.9876 | 0.000451 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-001075 |
BRD-K50010139-001-01-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.045589 | 0.316133 | 0.495585 | 0.409459 | 0.012719 | 0.017211 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-001075 |
BRD-K50168500-001-07-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | -0.048187 | 0.375022 | 0.703899 | 0.577897 | 0.293102 | 0.229335 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-001075 |
BRD-K51313569-001-07-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.755128 | -0.481695 | 0.013591 | 0.870025 | 0.112279 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-001075 |
BRD-K51791723-003-01-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.089678 | 1.283785 | 0.65535 | 0.687866 | 0.362677 | 0.423047 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001075 |
BRD-K51967704-001-03-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.149213 | 1.896798 | 0.699282 | 0.859627 | 2.069511 | 2.4947 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001075 |
BRD-K52313696-001-12-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.900237 | -3.726764 | 0.085669 | 0.926195 | 0.800535 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001075 |
BRD-K53414658-001-08-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.846425 | 0.522573 | 0.051128 | 0.919949 | 0.061329 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-001075 |
BRD-K53972329-001-07-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.868114 | -7.890445 | 0.088338 | 0.91632 | 0.288053 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-001075 |
BRD-K54955827-001-02-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.166733 | 0.742979 | 0.113894 | 1 | 0.663303 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-001075 |
BRD-K54997624-001-06-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.603347 | 0.079718 | -0.020331 | 0.791301 | 0.020663 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-001075 |
BRD-K55187425-236-05-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.093221 | -0.217655 | -0.022773 | 1 | 0.001805 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-001075 |
BRD-K56343971-001-14-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.97049 | 4.725758 | 0.455001 | 1 | 1.022776 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-001075 |
BRD-K56981171-001-02-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.283098 | 1.255443 | 0.442558 | 0.860209 | 1.628901 | 3.168126 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-001075 |
BRD-K57080016-001-15-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.580402 | 0.122702 | 0.048824 | 0.756037 | 0.004963 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-001075 |
BRD-K57169635-001-04-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.282076 | 0.492903 | 0.330631 | 0.480579 | 0.005079 | 0.027384 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-001075 |
BRD-K58435339-001-03-0 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.014767 | 0.394994 | 0.370166 | 0.721381 | 1.546434 | 1.668373 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-001075 |
BRD-K58529924-001-01-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.784421 | 0.825006 | 0.090069 | 0.82359 | 0.002737 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-001075 |
BRD-K58550667-001-08-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.187071 | 12.004385 | 0.653912 | 0.831149 | 0.083254 | 0.086569 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-001075 |
BRD-K59317601-001-05-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.726119 | 0.359756 | 0.161106 | 0.860868 | 0.069933 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-001075 |
BRD-K59369769-001-22-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.44749 | 0.241361 | 0.153402 | 1 | 0.581331 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-001075 |
BRD-K60866521-001-07-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.884215 | -0.193195 | -0.026013 | 0.923128 | 3.38359 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-001075 |
BRD-K60997853-001-02-3 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | -0.084381 | 0.380245 | 0.357013 | 0.660304 | 1.039911 | 0.690055 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-001075 |
BRD-K62196610-001-01-6 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.06539 | -0.030023 | -0.036621 | 1 | 5,017,256,896,865.015 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-001075 |
BRD-K62391742-001-09-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.838233 | -0.326241 | -0.099792 | 0.909632 | 0.185735 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-001075 |
BRD-K62627508-001-01-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.188819 | 0.712931 | 0.661067 | 0.577155 | 0.062686 | 0.121915 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-001075 |
BRD-K63504947-001-14-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.988785 | -0.18012 | 0.001894 | 0.993642 | 0.382155 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-001075 |
BRD-K63712959-001-01-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.657316 | -0.239702 | -0.166185 | 0.912039 | 0.000593 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-001075 |
BRD-K64052750-001-22-5 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.493522 | 1.044649 | 0.576922 | 0.712133 | 0.039862 | 2.555052 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-001075 |
BRD-K64881305-001-03-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.649668 | 1.77542 | 0.50318 | 1 | 0.023027 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-001075 |
BRD-K66175015-001-12-4 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.227144 | 0.279093 | 0.15932 | 0.63819 | 0.13201 | 1.156318 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-001075 |
BRD-K67844266-003-01-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.186742 | -1.293188 | 0.098655 | 1 | 0.247748 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-001075 |
BRD-K69001009-001-02-8 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.114345 | 0.528964 | 0.085344 | 1 | 0.287079 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-001075 |
BRD-K69694239-001-02-2 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.210717 | 5.787526 | 0.787275 | 0.68583 | 0.210075 | 0.230911 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-001075 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.